Travere Therapeutics
TVTX
126 hedge funds and large institutions have $1.09B invested in Travere Therapeutics in 2015 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 40 increasing their positions, 26 reducing their positions, and 8 closing their positions.
574% more call options, than puts
Call options by funds: $45.5M | Put options by funds: $6.75M
563% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 8
56% more funds holding
Funds holding: 81 → 126 (+45)
54% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 26
48% more capital invested
Capital invested by funds: $736M → $1.09B (+$356M)
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$25.4M |
| 2 |
Bank of New York Mellon
New York
|
+$9.08M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$8.72M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.67M |
| 5 |
CCM
Consonance Capital Management
New York
|
+$8.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$21.9M |
| 2 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$17M |
| 3 |
Goldman Sachs
New York
|
-$12.9M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$8.92M |
| 5 |
Jennison Associates
New York
|
-$7.57M |
TVTX Hedge Fund Activity: Q2 2015 in Review
126 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q2 2015, worth a combined $1.09B — up 48% from $736M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new TVTX positions and 8 closed out — a net gain of 45 holders — while 40 added to existing stakes and 26 trimmed.
The largest buyer was State Street, adding an estimated $25.4M. The largest seller was Broadfin Capital, cutting an estimated $21.9M.
- 126 institutional investors held Travere Therapeutics (TVTX) as of Q2 2015, up from 81 in Q1 2015.
- Funds reported $1.09B of Travere Therapeutics stock for Q2 2015, up 48% quarter-over-quarter.
- 53 funds opened new Travere Therapeutics positions in Q2 2015 and 8 closed out, a net change of +45 holders.
- The largest Travere Therapeutics buyer in Q2 2015 was State Street, an estimated $25.4M added.
- The largest Travere Therapeutics seller in Q2 2015 was Broadfin Capital, an estimated $21.9M sold.
Based on aggregated 13F filings for Q2 2015.